Enhanced bioavailability of polyunsaturated fatty acids
View Patent ↗Described herein are pharmaceutical compositions providing enhanced bioavailability of polyunsaturated fatty acids and methods of manufacturing the same. In particular, described herein are pharmaceutical compositions comprising soft enteric capsules that provide enhanced bioavailability of omega-3 polyunsaturated fatty acids. The oral pharmaceutical compositions described herein are useful as nutritional supplements or for the treatment of cardiovascular-related diseases, such as hyper dyslipidemia and moderate to high triglyceride levels.
1. An oral pharmaceutical composition comprising an enteric soft capsule shell consisting essentially of:
about 25% to about 40% by weight of gelatin;
about 9% to about 11% by weight of an enteric polymer;
about 10% to about 22% by weight of a plasticizer;
about 1% to about 4% by weight of an alkali neutralizing agent; and
about 19% to about 65% by weight of a solvent;
wherein the enteric polymer and gelatin is in a mixture in a 1:2.6 weight ratio of the enteric polymer to the gelatin; and
wherein the shell encapsulates a matrix fill comprising at least 94% by weight eicosapentaenoic free fatty acid (EPA) and less than 1% by weight docosahexaenoic acid (DHA); wherein upon administration to a subject, an EPA C max ratio of a high-fat fed subject and a fasted subject fed a low-fat diet is less than 3:1.
2. The composition of claim 1 , wherein the fill comprises about 250 mg to about 1000 mg of EPA.
3. The composition of claim 1 , wherein upon administration to a subject, the subject experiences a minimal incidence of one or more of eructation, abdominal discomfort, nausea, diarrhea, fishy aftertaste, or fishy odor.
4. The composition of claim 1 , wherein the capsule shell and matrix fill composition are stable for at least 1 year at 25° C., 60% relative humidity.
5. The composition of claim 1 , wherein the capsule shell does not dissolve in simulated gastric fluid (pH 1.2) for at least 1 hour, and begins dissolution in simulated intestinal fluid (pH 6.8) within about 15 minutes.
6. The composition of claim 1 , wherein upon administration to a subject the composition provides a mean plasma EPA C max of about 122 mg/L to about 226 mg/L and one or more of the following pharmacokinetic parameters:
(a) a mean plasma EPA T max of about 5 hours to about 6 hours;
(b) a mean plasma EPA AUC 0→τ of about 1840 h·mg/L to about 2860 h·mg/L;
(c) a mean plasma EPA AUC 0→∞ of about 2040·mg/L to about 3000 mg/L;
(d) a mean EPA half-life (t½) of about 37 hours to about 43 hours; or
(e) a mean EPA overall elimination rate constant (k e1 ) of about 0.019 h −1 to about 0.020 h −1 .
7. The composition of claim 1 , wherein upon administration to a subject the composition provides one or more of the following pharmacokinetic parameters:
(a) a mean plasma EPA T max of about 6 hours under fasting/low fat conditions;
(b) a mean plasma EPA C max of about 122 mg/L under fasting/low fat conditions;
(c) a mean plasma EPA AUC 0→τ of about 1840 h·mg/L under fasting/low fat conditions;
(d) a mean plasma EPA AUC 0→∞ of about 2040·mg/L under fasting/low fat conditions;
(e) a mean EPA half-life (t½) of about 43 hours under fasting/low fat conditions; or
(f) a mean EPA overall elimination rate constant (k e1 ) of about 0.019 h −1 under fasting/low fat conditions;
or
(g) a mean plasma EPA C max of about 226 mg/L under fed/high fat conditions;
(h) a mean plasma EPA AUC 0→τ of about 2860 h·mg/L under fed/high fat conditions;
(i) a mean plasma EPA AUC 0→∞ of about 3000 mg/L under fed/high fat conditions.
8. The composition of claim 1 , wherein upon administration to a subject, the EPA has a bioavailability of about 2000% of the bioavailability of a reference pharmaceutical composition comprising eicosapentaenoic ethyl ester under fasted/low fat conditions.
9. The composition of claim 8 , wherein the reference pharmaceutical composition comprises eicosapentaenoic ethyl ester in a soft gel capsule.
10. The composition of claim 1 , wherein upon administration to a subject the composition does not induce a substantial increase in LDL level relative to baseline.
11. The composition of claim 1 , wherein the composition is useful for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms of a cardiovascular-related disease, including but not limited to hyperlipidemia or hypertriglyceridemia.
12. The composition of claim 1 , wherein the composition is useful for treating, retarding the progression of, delaying the onset of, prophylaxis of, amelioration of, or reducing the symptoms a medical condition comprising: cardiovascular-related diseases, hyperlipidemia, hypertriglyceridemia, hypertension, hypercholesterolemia, mixed dyslipidemia, sitosterolemia, atherosclerosis, or a combination thereof.
13. The composition of claim 1 , wherein the enteric polymer is an acrylic and methacrylic acid copolymer; the plasticizer is glycerol and triethyl citrate; the alkali neutralizing agent is selected from the group consisting of ammonium hydroxide and sodium hydroxide; and the solvent is water.